Clinical trial · Interventional
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-96673 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT04860466CI-TRIAL-00081635terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Business objectives have changed.
Summary
Brief summary (as posted)
The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL). The study will be conducted in 2 parts: Part A, monotherapy dose escalation and Part B, monotherapy dose expansion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CC-96673 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Administration of CC-96673
- description
- CC-96673 will be administered on a once weekly (Q1W) or once every 2 weeks (Q2W) schedule
- interventionNames
- Drug: CC-96673
Primary outcomes (3)
- measure
- Incidence of Adverse Events (AEs)
- timeFrame
- From enrollment until at least 28 days after completion of study treatment
- description
- An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an AE.
- measure
- Dose-limiting toxicity (DLT)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Participants must satisfy the following criteria to be enrolled in the study: 1. Participant (male or female) is ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Participant must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. 3. Participant is willing and able to adhere to the study visit schedule and other protocol requirements. 4. Participant must have a history of NHL that has relapsed or progressed. 5. Participant has an ECOG PS of 0 or 1. 6. Participants must have acceptable laboratory values as specified in the protocol. Exclusion Criteria: 1. Participant has cancer with symptomatic central nervous system (CNS) involvement 2. Participant is on chronic systemic immunosuppressive therapy or corticosteroids or subjects with clinically significant graft-versus-host disease (GVHD). Intranasal, inhaled, topical, or local corticosteroid injections, or steroids as premedication for hypersensitivity reactions are exceptions to this criterion. 3. Inadequate cardiac function or significant cardiovascular disease 4. Participant has received prior investigational therapy directed at CD47 or SIRPα. 5. Participant had major surgery ≤ 2 weeks prior to starting CC-96673. 6. Participant is a pregnant or lactating female or intends to become pregnant during participation of the study. 7. Participant has known active human immunodeficiency virus (HIV) infection. 8. Participant has active hepatitis B or C (HBV/HCV) infection. 9. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants. 10. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia. 11. History of concurrent second cancers requiring active, ongoing systemic treatment. 12. Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 13. Participant has active, uncontrolled, or suspected infection. Other protocol defined inclusion/exclusion criteria could apply.
References
Publications (0)
Data not yet available
No reference posted for this study.